Abstract:N-Acetylaspartate (NAA) is the second most abundant organic metabolite in the brain, but its physiological significance remains enigmatic. Toxic NAA accumulation appears to be the key factor for neurological decline in Canavan disease-a fatal neurometabolic disorder caused by deficiency in the NAA-degrading enzyme aspartoacylase. To date clinical outcome of gene replacement therapy for this spongiform leukodystrophy has not met expectations. To identify the target tissue and cells for maximum anticipated treatment benefit, we employed comprehensive phenotyping of novel mouse models to assess cell type-specific consequences of NAA depletion or elevation. We show that NAA-deficiency causes neurological deficits affecting unconscious defensive reactions aimed at protecting the body from external threat. This finding suggests, while NAA reduction is pivotal to treat Canavan disease, abrogating NAA synthesis should be avoided. At the other end of the spectrum, while predicting pathological severity in Canavan disease mice, increased brain NAA levels are not neurotoxic per se. In fact, in transgenic mice overexpressing the NAA synthesising enzyme Nat8l in neurons, supra-physiological NAA levels were uncoupled from neurological deficits. In contrast, elimination of aspartoacylase expression exclusively in oligodendrocytes elicited Canavan disease like pathology. Although conditional aspartoacylase deletion in oligodendrocytes abolished expression in the entire CNS, the remaining aspartoacylase in peripheral organs was sufficient to lower NAA levels, delay disease onset and ameliorate histopathology. However, comparable endpoints of the conditional and complete aspartoacylase knockout indicate that optimal Canavan disease gene replacement therapies should restore aspartoacylase expression in oligodendrocytes. On the basis of these findings we executed an ASPA gene replacement therapy targeting oligodendrocytes in Canavan disease mice resulting in reversal of pre-existing CNS pathology and lasting neurological benefits. This finding signifies the first successful post-symptomatic treatment of a white matter disorder using an adeno-associated virus vector tailored towards oligodendroglial-restricted transgene expression.

Deep mutational scanning reveals a correlation between degradation and toxicity of thousands of aspartoacylase variants

Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant

Mapping the degradation pathway of a disease-linked aspartoacylase variant

Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme

Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease

Identification of potential pharmacological chaperones that selectively stabilize mutated Aspartoacylases in Canavan disease

Structural modeling of p.V31F variant in the aspartoacylase gene

Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity

A mutational atlas for Parkin proteostasis

Serial Deletion Reveals Structural Basis and Stability for the Core Enzyme Activity of Human Glutaminase 1 Isoforms: Relevance to Excitotoxic Neurodegeneration.

A novel Aspartoacylase (ASPA) Gene Mutation in Canavan Disease

Proteostasis Associated Variants in HSPB5 Destabilize the αB-crystallin Domain

Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy

Study of the Uncertainly Significant Variants reveal major Structural, Functional fluctuations leading to potential Disease-Based Associations

Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease

Two patients with Canavan disease and structural modeling of a novel mutation

A Novel Mutation in Aspartoacylase Gene; Canavan Disease

New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion

Assessing the relative importance of the biophysical properties of amino acid substitutions associated with human genetic disease

High-content analysis of proteostasis capacity in cellular models of amyotrophic lateral sclerosis (ALS)

Reduced protein stability of 11 pathogenic missense STXBP1/MUNC18-1 variants and improved disease prediction